

RECEIVED
CENTRAL FAX CENTER

NOV 29 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-21. (Cancelled).

22. (New) A compound comprising:

a tumor-seeking biomolecule;

an intercalating moiety coupled to the tumor-seeking biomolecule and comprising acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole, or a compound that exhibits cytostatic activity; and

a metal complexed with the intercalating moiety.

23. (New) The compound of claim 22, wherein the metal is a radioactive metal.

24. (New) The compound of claim 23 wherein the radioactive metal is a γ -emitting nuclide.

25. (New) The compound of claim 23, wherein the radioactive metal is selected from Tc-99m, Re-186, Re-188 and Mn.

26. (New) The compound of claim 22, wherein the tumor-seeking biomolecule is selected from the group consisting of peptides and proteins

27. (New) The compound of claim 23, wherein the tumor-seeking biomolecule is selected from the group consisting of peptides and proteins

28. (New) The compound of claim 22, wherein the tumor-seeking biomolecule is selected from somatostatin-receptor binding molecules, neurotensin-receptor binding molecules, bombesin-receptor binding molecules, GPIIb/IIIa-receptor binding molecules, antibodies, penetratines, and glycoproteins.

29. (New) The compound of claim 23, wherein the tumor-seeking biomolecule is selected from somatostatin-receptor binding molecules, neurotensin-receptor binding molecules, bombesin-receptor

binding molecules, GPIIb/IIIa-receptor binding molecules, antibodies, penetratines, and glycoproteins.

28. (New) The compound of claim 22, wherein the tumor-seeking biomolecule is selected from anti-sense oligonucleotides, deoxy-uridine, and spermidine.

29. (New) The compound of claim 23, wherein the tumor-seeking biomolecule is selected from anti-sense oligonucleotides, deoxy-uridine, and spermidine.

30. (New) A composition comprising:

at least one of an excipient and a diluent; and

a compound comprising:

a tumor-seeking biomolecule;

an intercalating moiety coupled to the tumor-seeking biomolecule and comprising acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole, or a compound that exhibits cytostatic activity; and

a metal complexed with the intercalating moiety.

31. (New) The composition of claim 30, wherein the metal is a radioactive metal.

32. (New) The composition of claim 30, wherein the tumor-seeking biomolecule is selected from the group consisting of peptides and proteins

33. (New) The composition of claim 31, wherein the tumor-seeking biomolecule is selected from the group consisting of peptides and proteins

34. (New) The composition of claim 30, wherein the tumor-seeking biomolecule is selected from somatostatin-receptor binding molecules, neurotensin-receptor binding molecules, bombesin-receptor binding molecules, GPIIb/IIIa-receptor binding molecules, antibodies, penetratines, and glycoproteins.

35. (New) The composition of claim 31, wherein the tumor-seeking biomolecule is selected from somatostatin-receptor binding molecules, neurotensin-receptor binding molecules, bombesin-receptor binding molecules, GPIIb/IIIa-receptor binding molecules, antibodies, penetratines, and glycoproteins.

36. (New) The composition of claim 30, wherein the tumor-seeking biomolecule is selected from anti-sense oligonucleotides, deoxy-uridine, and spermidine.

37. (New) The composition of claim 31, wherein the tumor-seeking biomolecule is selected from anti-sense oligonucleotides, deoxy-uridine, and spermidine.

38. (New) A method of using a composition, the method comprising:

administering a composition to a medical patient, wherein the composition includes a compound comprising:

a tumor-seeking biomolecule;

an intercalating moiety coupled to the tumor-seeking biomolecule and comprising acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole, or a compound that exhibits cytostatic activity; and

a metal complexed with the intercalating moiety.

39. (New) The method of claim 38, wherein the composition is administered to diagnose at least one of a tumor and a malignancy.

40. (New) The method of claim 38, wherein the composition is administered to treat at least one of a tumor and a malignancy.